ALBANY, N.Y.–(BUSINESS WIRE)–#AMRI–Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced the appointment of Niall Condon as president of its Manufacturing Division, with immediate effect. Condon will drive growth and be responsible for operational delivery of Curia’s commercial manufacturing services and products, including API and Drug Product. He will serve as … [Read more…]
Zone of potential insufficiency, where storage demand outstrips capacity, could be >25 zettabytes during 2030 Approximately 75% of all data stored to be ‘cold’ data, infrequently accessed ‘just in case’ it is needed Data retention times are ‘indefinite,’ say key industry executives, never deleted SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), a company … [Read more…]
WESTLAKE, Ohio–(BUSINESS WIRE)–Nordson Corporation (Nasdaq: NDSN) today announced it will release third quarter fiscal year 2022 earnings on August 22, 2022 after the close of the market. Nordson will host its quarterly webcast on Tuesday, August 23, 2022. Date: August 23, 2022 Time: 8:30 AM ET Listen via Internet: https://events.q4inc.com/attendee/942030981 Investors who are interested in … [Read more…]
NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that it has appointed Wendy K. Chung, M.D., Ph.D., to its Board of Directors. “Wendy is a tremendous addition to our Board of Directors. Her … [Read more…]
TAEUS® now protected by 53 patents issued globally, including 31 in the U.S. New U.S. patents expand potential licensing opportunities in data management ANN ARBOR, Mich.–(BUSINESS WIRE)–$NDRA #NALFD—ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent & Trademark Office has issued … [Read more…]
OT166 is a potential first-in-class non-invasive selective RGD integrin inhibitor, delivered as eye drop, for the treatment of diabetic retinopathy OT166 has the potential to address an unmet need for an earlier, non-invasive ophthalmic treatment for diabetic retinopathy BOSTON–(BUSINESS WIRE)–OcuTerra Therapeutics, Inc. (“OcuTerra”), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases … [Read more…]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, and Julie Feder, Chief Financial Officer, of Aura will participate in a fireside chat at the 2022 Hybrid BTIG … [Read more…]
LEWISVILLE, Texas–(BUSINESS WIRE)–Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced a strategic partnership agreement with CGBio, a developer of innovative, synthetic bone grafts currently used clinically in Asia for spine, orthopedic, trauma and dental applications. The two companies will work together for clinical development and commercialization … [Read more…]
Total revenues increased 29% year-over-year (Y/Y) to $911 million; total product revenues of $664 million (+15% Y/Y) Jakafi® (ruxolitinib) net product revenues of $598 million in Q2’22 (+13% Y/Y) driven by volume growth; raising the bottom end of full year guidance to new range of $2.36 to $2.40 billion Opzelura™ (ruxolitinib) cream approved as first … [Read more…]
Subjects with Long COVID receiving AXA1125 experienced a clinically and statistically significant improvement in mental (p=0.0097) and physical (p=0.0097) fatigue scores compared to placebo subjects Responders to AXA1125 demonstrated significantly improved scores during a 6 minute walk test No emergent adverse events (AEs) or serious adverse events (SAEs) occurred Regulatory meetings are planned to discuss … [Read more…]
